Hidrocloruro De Sevelámero Waymade (Sevelamer Hydrochloride)

Hidrocloruro De Sevelámero Waymade is indicated for the management of hyperphosphatemia in specific patient populations.

• Patients with chronic kidney disease (CKD) who are on maintenance hemodialysis.
• Individuals receiving peritoneal dialysis who require phosphate control.
• Adults whose dietary phosphate intake exceeds renal excretory capacity.
• Cases where dietary phosphate restriction alone is insufficient to achieve target serum phosphate levels.
• Situations where clinicians aim to reduce the risk of vascular calcification associated with high phosphate.

• Sevelamer hydrochloride is a non‑calcium, non‑metal polymer that binds phosphate ions in the gastrointestinal lumen. The positively charged polymer exchanges its chloride ions for phosphate anions, forming insoluble complexes that are excreted in the feces. By limiting intestinal absorption of dietary phosphate, the drug lowers circulating phosphate concentrations, helping to maintain serum phosphate within the target range for patients with renal impairment.

Adverse reactions to Hidrocloruro De Sevelámero Waymade have been reported, ranging from mild to serious.

Common

• Nausea or vomiting, often transient after the first doses.
• Constipation or diarrhea, varying in severity.
• Abdominal discomfort, bloating, or gas.
• Metallic or chalky taste in the mouth.

Serious

• Severe gastrointestinal obstruction or ileus requiring medical evaluation.
• Hypercalcemia, particularly when used with calcium‑based phosphate binders.
• Allergic reactions such as rash, pruritus, urticaria, or angioedema.
• Metabolic acidosis in patients with existing acid‑base disturbances.

Clinicians should consider several precautions when prescribing Hidrocloruro De Sevelámero Waymade to ensure safe and effective use.

• Assess baseline serum phosphate, calcium, and bicarbonate levels before initiating therapy.
• Monitor laboratory values regularly, adjusting dose to maintain target phosphate range.
• Use caution in patients with a history of bowel obstruction, strictures, or severe constipation.
• Avoid concurrent use of calcium‑based phosphate binders without careful monitoring of calcium balance.
• Consider the risk of metabolic acidosis in patients with advanced renal disease or respiratory compromise.
• Educate patients to take the medication with meals and to maintain adequate fluid intake.

Sevelamer hydrochloride may interact with other oral agents, affecting absorption or electrolyte balance.

Avoid

• Concomitant use with calcium carbonate or calcium acetate without monitoring calcium levels.
• Simultaneous administration with oral iron supplements, as sevelamer can reduce iron absorption.

Use with caution

• Vitamin D analogues, because altered phosphate levels may affect calcium metabolism.
• Antacids containing aluminum or magnesium, which may bind to sevelamer and reduce its efficacy.
• Lipid‑lowering agents such as statins, where timing of dosing may be adjusted to avoid binding.
• Certain antibiotics (e.g., quinolones) that require an acidic gastric environment for absorption.